With no single test to diagnose multiple sclerosis (MS), MS diagnosis and patient management remain challenging. This Multiple Sclerosis Awareness Week, we want to raise awareness of those living with MS and support the providers helping to manage their care. To help providers develop precise management strategies for MS, Labcorp offers the Multiple Sclerosis Monitoring Profile, which combines two powerful biomarkers: NfL and GFAP. Learn how our extensive portfolio of MS tests can help providers and their patients: https://spr.ly/60430M2O5 #MultipleSclerosis
关于我们
Clear and confident health care decisions begin with questions. At Labcorp, we’re constantly in pursuit of answers. As a global leader of innovative and comprehensive laboratory services, we help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Our more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about Labcorp (NYSE: LH) at www.labcorp.com.
- 网站
-
https://www.labcorp.com
Labcorp的外部链接
- 所属行业
- 医院和医疗保健
- 规模
- 超过 10,001 人
- 总部
- Burlington，North Carolina
- 类型
- 上市公司
地点
-
主要
获取路线
531 South Spring Street
US，North Carolina，Burlington，27215
Labcorp员工
动态
-
A warm welcome to our 30 new India interns at Labcorp! These students from universities across India are kick-starting their careers in project management, clinical research, immunology and immunotoxicology, specimen solutions and IT. We look forward to learning from their perspectives and supporting their growth as we work together to improve health and improve lives around the world. Interested in an internship with Labcorp? Learn more here: https://spr.ly/6047I9R4S #JoinThePursuit #EarlyCareers #Internships
-
-
Today, we entered into an agreement to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, we will acquire BioReference Health’s laboratory testing businesses focused on oncology and oncology-related clinical testing services across the United States. Read the full announcement here: https://spr.ly/60470y18f BioReference #Oncology #ClinicalDrugTesting
-
The rise of at-home and direct-to-consumer testing is transforming healthcare by offering people more opportunities to take charge of their health. However, the healthcare industry faces challenges in providing better access and affordability. Amy Summy, Labcorp Executive Vice President and Chief Marketing Officer, will join a panel discussion at the 32nd Annual Precision Med Tri-Con that focuses on: ?? Consumer-initiated testing growth ?? Access and regulatory challenges ?? Evolving diagnostic landscape Learn more about Labcorp OnDemand's approach to convenient, consumer-initiated testing solutions: https://lnkd.in/d8VqWU6R #PrecisionMedTriCon #HealthcareInnovation #DirectAccessTesting #PatientEmpowerment
-
-
We are celebrating International Women's Day by recognizing the incredible women who work at Labcorp. Today and every day, we are committed to empowering women to make informed decisions about their health and supporting progress in science and healthcare. Join us in recognizing the invaluable contributions of women in science, healthcare and beyond. #IWD2025 #AccelerateAction #InternationalWomensDay #WomensHealth
-
Comprehensive Genomic Profiling (CGP) provides significant benefits in managing complex cancer mutations, potentially leading to more effective treatments.?We're proud to support improving access to CGP to unlock more personalized patient care. #CGP #ComprehensiveGenomicProfiling
???Let’s unlock the untapped potential of #ComprehensiveGenomicProfiling (CGP)! We are thrilled to announce the publication of our recommendations on how to improve patient access to CGP:?"The untapped potential of Comprehensive Genomic Profiling"! These recommendations are developed by ECGP in collaboration with their renowned independent experts and patient advocate Steering Group. Patient access to comprehensive genomic profiling across Europe remains limited due to various challenges. Through our recommendations, we outline strategies and actionable insights to address them: ????ECGP recommendations ?? Improve?awareness?on the value of Comprehensive Genomic Profiling (CGP) ?? Establish clear?funding and reimbursement pathways?for technologies like CGP ?? Ensure the?implementation requirements?are realised to ensure patient access to CGP, guidelines, (data) infrastructure, sufficient and capable workforce and stimulating procurement policies. ?? Enhance?collaboration?among policymakers, industry, healthcare professionals, and patient advocacy groups, to improve access to CGP ?? Read the recommendations here: https://lnkd.in/es4eC6ME Join us in our mission to unlock the potential of personalized medicines by increasing access to comprehensive genomic profiling! Feel free to connect with Matias Olsen to further discuss this topic. Find out more about ECGP: https://ecgp.eu/ Amgen Guardant Health Illumina Labcorp Menarini Stemline MSD Vintura #AdvancedDiagnostics #GenomicProfiling #ADx #HealthcareInnovation #ECGP #PatientAccess #EUCOPE #HealthEquity #CGP
-
-
Would you know when to suspect a patient has multiple myeloma? Access a three-step quick guide to identifying patients who may have multiple myeloma and expedite referrals. Early detection is key. Download the guide here: https://spr.ly/6042LqR8r #Myeloma #MultipleMyeloma #MyelomaActionMonth #MultipleMyelomaAwarenessMonth
-
-
Over 30 million people in the U.S. live with a rare disease. And out of more than 7,000 known rare diseases, only a few hundred have approved therapies. Using Labcorp's real-world data and genomic insights from testing conducted on over 5 million patients, researchers can uncover new targets and accelerate therapeutic development. Labcorp remains committed to leveraging our real-world data solutions to help biopharma customers identify new potential targets, accelerate therapeutic development and bring treatments to patients who need them faster. Learn more: https://spr.ly/6040Lgb6K #RareDiseaseDay #RealWorldData #PrecisionMedicine #Biopharma
-
In patients with advanced gastric and gastroesophageal junction cancers, CLAUDIN18.2 can point to a new path. Labcorp now offers a companion diagnostic test for CLDN18.2 using the VENTANA CLDN18 (43-14A) RxDx immunohistochemistry assay to detect CLDN18.2 protein expression levels. If you think your patient might benefit from testing, please reach out to Labcorp at [email protected] #GastricCancer #CancerDiagnostics #PersonalizedMedicine
-
-
Labcorp introduces Labcorp? Plasma Complete?, a ctDNA-based comprehensive genomic profiling solution for advanced solid tumors. This comprehensive 521-gene panel liquid biopsy test offers genomic insights from a simple blood draw, enabling oncologists to make personalized treatment decisions when tumor tissue testing is not feasible. Read the full press release: https://spr.ly/6047L3JDZ #LiquidBiopsy #CancerCare #Oncology #LabcorpOncology